Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting

Core Insights - Immatics N.V. is set to present data on its lead product candidate, IMA203 TCR T-cell therapy, at the 2025 ASCO Annual Meeting from May 30 to June 3, 2025 [1] - The presentations will include updated data from the Phase 1b trial of IMA203 in metastatic melanoma patients, with longer follow-up and additional data from uveal melanoma patients [2] - A trial-in-progress poster on the ongoing Phase 3 clinical trial, SUPRAME, will also be presented, evaluating IMA203 in patients with unresectable or metastatic cutaneous melanoma [3] Presentation Details - Oral presentation titled "Phase 1 clinical update of IMA203, an autologous TCR-T targeting PRAME in patients with PD1 refractory metastatic melanoma" will be held on May 31, 2025 [4] - Poster presentation titled "SUPRAME: A phase 3 trial comparing IMA203 vs investigator's choice in patients with previously treated advanced cutaneous melanoma" will take place on June 2, 2025 [4] Product Information - IMA203 is an engineered T-cell receptor therapy targeting PRAME, an intracellular protein with minimal expression on healthy tissues, demonstrating a favorable clinical profile [5] - The therapy has a turnaround time of approximately 14 days and is currently being evaluated in a registration-enabling randomized controlled Phase 3 trial [6] Company Overview - Immatics focuses on discovering true targets for cancer immunotherapies and developing specific T-cell receptors to enhance T-cell responses against these targets [7] - The company aims to deliver effective T-cell therapies and explore new treatment avenues for cancer patients [7]